Polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).
|NCPE Assessment Process||Ongoing|
|Rapid Review commissioned||03/12/2019|
|Rapid Review completed||27/01/2020|
|Rapid Review Outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||26/02/2020|
|Pre-submission consultation with Applicant||31/03/2020|
|Current status||Awaiting HTA submission from Applicant|